MD1003-AMN MD1003 in Adrenomyeloneuropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day over placebo in the clinical improvement (walking tests) of patients with adrenomyeloneuropathy
Epistemonikos ID: 0869e675ea1ee32210771b0c0207f7c6b74364b0
First added on: Mar 31, 2022